1. Neoadjuvant chemotherapy in patients with stage IVB uterine serous carcinoma: a Turkish multicentric study
- Author
-
Mehmet Unsal, Cigdem Kilic, Caner Cakir, Fatih Kilic, Burak Ersak, Sema Karakas, Nedim Tokgozoglu, Bulut Varli, Okan Oktar, Gunsu Kimyon Comert, Isa Aykut Ozdemir, Nurettin Boran, Tayfun Toptas, Isin Ureyen, Vakkas Korkmaz, Salih Taskin, Ozlem Moraloglu Tekin, Yaprak Ustun, Tolga Tasci, Firat Ortac, and Taner Turan
- Subjects
neoadjuvant chemotherapy ,advanced stage ,uterine serous carcinoma ,survival ,Gynecology and obstetrics ,RG1-991 - Abstract
The aim of this study was to evaluate the prognostic factors for and determine the effect of neoadjuvant chemotherapy (NACT) on oncologic outcome in stage IVB pure serous endometrial carcinoma patients who received taxane and platinum. Forty-two patients with 2009 International Federation of Gynecology and Obstetrics (FIGO) stage IVB uterine serous carcinoma were enrolled from six gynecologic oncology centers and a study group was created. The study group had a 2-year disease-free survival (DFS) of 32% and 2-year disease-specific survival (DSS) of 73%. On univariate analysis; lymphadenectomy (not performed vs. performed), paraaortic lymph node metastasis (positive vs. negative) and number of metastatic lymph node count (≤5 vs. >5) were found to have statistical significance for DFS (p
- Published
- 2023
- Full Text
- View/download PDF